Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.
Tumor protein p73 (TP73) has been commonly tagged as a putative tumor suppressor, but it may positively regulate the growth and stemness of cancer stem cells.
A recent article by researchers from Hangzhou Medical College reports data from studies that aimed to investigate the mechanisms behind the antitumor activity of the synthetic retinoid analogue WYC-209.
Plexium Inc. has described the efforts that led to the discovery of PLX-4545, an orally bioavailable molecular glue degrader of IKZF2 for the treatment of cancer that is currently undergoing evaluation in a phase I study in healthy volunteers.
Artificial intelligence (AI) drug discovery company Noetik Inc. has closed on an oversubscribed $40 million series A financing round. The company plans to use the money to expand its atlas of human cancer biology with its in vivo CRISPR platform to advance a pipeline of cancer therapeutics to the clinic. In describing its approach, the company said that making a genuine impact on drug discovery requires computational capabilities to understand and simulate disease biology at the patient level, identifying the right targets and matching them with the right therapies.
Grail Inc.’s multi-cancer early detection test, Galleri, preferentially screens for aggressive prostate cancer, addressing concerns about overdiagnosis and subsequent overtreatment of indolent cancers, a study published in JCO Precision Oncology demonstrated.
Microbiotica Ltd. is poised to advance two of its microbiome-derived products into the clinic after securing regulatory approval and fresh finance. The first live bacterial therapeutic, MB-097, will be tested in combination with Keytruda (pembrolizumab) in patients with advanced melanoma who have not responded to treatment with immune checkpoint inhibitors. The second product, MB-310, is a once-daily oral therapy for treating the inflammatory bowel disease, ulcerative colitis.
A Contineum Therapeutics Inc. patent describes a crystalline form of lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of brain cancer, glioblastoma, idiopathic pulmonary fibrosis, inflammatory disorders, multiple sclerosis, neurodegeneration, neuropathic pain and scleroderma, among others.
Work at the Korea Institute of Radiological and Medical Sciences and Korea Research Institute of Chemical Technology has led to the identification of new poly(ADP-ribose) polymerase tankyrase (TNKS) inhibitors potentially useful for the treatment of cancer.
RSS
